泰州牙齿松动能修复吗泰州镶烤瓷牙,泰州牙齿都掉了怎么办啊,泰州种植牙价格,泰州牙齿矫正前后对比,泰州牙科种植牙多少钱,泰州北极星齿科 单科矫正,泰州镶牙烤瓷牙多少钱

BEIJING, Oct. 8 (Xinhua) -- Authorities hope to innovate social management by restructuring its governmental organ, an official said in an interview with Xinhua and the People's Daily on Saturday.The organ, the Central Committee for Comprehensive Social Management, was renamed and restructured in a meeting last month from the previous Central Committee for Comprehensive Management of Public Security.With 11 more departments than the previous one, the new committee, with 51 departments, is expected to strengthen and innovate social management so as to build a harmonious, stable society, an official from the general office of the committee said.The official said the renaming and restructuring of the committee came as the former's concepts, mechanisms and measures fell behind China's fast social and economic development after its 20 years of existence.The official said the new committee will primarily address some major issues that could threaten social harmony and stability, such as criminal gangs and juvenile delinquency, while enacting laws and regulations for social management.

WASHINGTON, Oct. 13 (Xinhua) -- U.S. researchers have corrected sickle cell disease in adult laboratory mice that had been bred to have the inherited blood disorder by activating production of a special blood component, according to a study published online Thursday in the journal Science.Sickle cell disease results from an abnormality in hemoglobin, the protein found in red blood cells that is responsible for transporting oxygen throughout the body. People living with sickle cell disease have two copies of an altered gene that produces sickle hemoglobin instead of normal adult hemoglobin. Sickle hemoglobin changes shape after releasing its oxygen, causing the red blood cell to become stiff, misshapen and sticky, and slowing blood flow to tissues. This process damages organs and causes pain.The study tested a new approach to increasing the production of a third form of hemoglobin -- fetal hemoglobin. Production of fetal hemoglobin predominates before birth, but turns off thereafter as adult hemoglobin production takes over. People with sickle cell disease are unable to make normal adult hemoglobin, and instead make sickle hemoglobin starting in infancy.An elevated level of fetal hemoglobin within the red blood cell reduces the tendency of sickle hemoglobin to change the shape of red blood cells. Considerable research has shown that the drug hydroxyurea increases production of fetal hemoglobin and reduces the number of pain crises and other complications of sickle cell disease in adults and children. However, not all patients respond well to hydroxyurea, and adverse side effects are a concern.The current study explores a more targeted approach to increasing fetal hemoglobin production. It builds upon earlier studies that discovered a protein called BCL11A normally suppresses the production of fetal hemoglobin soon after birth. The researchers viewed the BCL11A protein as a target for therapy and decided to see what would happen if they blocked production of the protein.The paper details how the research team silenced the mouse gene that produces the BCL11A protein in mice with sickle cell disease. Silencing the gene turned off production of the BCL11A protein and allowed the adult mice to continue to produce fetal hemoglobin. It appears to have eliminated disease symptoms without affecting other aspects of blood production."This discovery provides an important new target for future therapies in people with sickle cell disease," said Susan Shurin, acting director of the U.S. National Heart, Lung, and Blood Institute, which co-funded the study. "More work is needed before it will be possible to test such therapies in people, but this study demonstrates that the approach works in principle."Approximately 100,000 Americans live with sickle cell disease. It is most prevalent in people of African, Hispanic, Mediterranean, and Middle Eastern descent. There is no widely available cure for sickle cell disease. Bone marrow transplants have cured some patients, but the treatment is not without risk and most patients do not have relatives who can donate compatible and healthy bone marrow to them.

VIENNA, Oct. 7 (Xinhua) -- A sculpture of late Soviet cosmonaut Yuri Gagarin was presented to the UN Office in Vienna (UNOV) Friday to celebrate "50 Years of Human Spaceflight," the theme of the World Space Week 2011.In 1961, Gagarin completed an orbit around the Earth aboard the Vostok 1 spacecraft, serving as a pioneer of human spaceflight.The sculpture is a gift from the Russian government and would be placed at the Permanent Exhibit of the United Nations Office for Outer Space Affairs (UNOOSA).Attendants of the ceremony include UNOV Director-General Yury Fedotov, UNOOSA Director Mazlan Othman and Head of the Russian Permanent Mission Vladimir Voronkov."Outer space is one of the most exciting and challenging topics, and perhaps of all the important topics on the agenda of the United Nations, none quite captures our imagination like outer space," Othman said in her statement.Meanwhile, speaking highly of Gagarin's achievement 50 years ago, Fedotov stressed that the purpose of the development and utilization of outer space must be to the benefit of all mankind.The UN official said that relevant UN agencies would provide technical assistance to all countries to develop outer space and ensure the benefits in peaceful purpose.On Dec. 6, 1999, the 55th United Nations General Assembly declared the World Space Week to be held every year during Oct. 4-10.

WASHINGTON, Oct. 9 (Xinhua) -- U.S. researchers have found a way to block, in an animal model, the damaging inflammation that contributes to many disease conditions. In their report receiving early online publication Sunday in Nature Biotechnology, researchers describe using small interfering RNA technology to silence the biochemical signals that attract a particular group of inflammatory cells to areas of tissue damage."The white blood cells known as monocytes play a critical role in the early stages of the immune response," says Matthias Nahrendorf, of the Massachusetts General Hospital (MGH) Center for Systems Biology, the paper's senior author. "We now know there are two subsets of monocytes -- an inflammatory subset that defends against pathogens and a reparative subset that supports healing. But if the inflammatory response is excessive, it can block the healing process and exacerbate conditions such as heart disease and cancer."Cells damaged by injury or disease release a cocktail of chemicals called cytokines that attract immune cells to the site of the damage. Inflammatory monocytes are guided to sites of tissue injury by a receptor protein called CCR2, and the MGH-led team devised a strategy targeting that molecule to block the inflammatory process but not the action of the reparative monocytes.Small interfering RNA (siRNA) technology prevents production of specific proteins by binding to associated messenger RNA molecules and preventing their translation. However, the technique requires extreme precision in developing the right siRNA molecule and delivering it to the correct cellular location.To make sure that their siRNA preparation targeted the right monocytes, researchers first confirmed that its use reduced levels of CCR2 in monocytes and increased levels of the fragments produced when siRNA binds to its target. They then showed that monocytes from mice treated with the siRNA preparation were unable to migrate towards CCR2's usual molecular target. Experiments in animal models of several important diseases showed that the siRNA preparation reduced the amount of cardiac muscle damaged by a heart attack, reduced the size and the number of inflammatory cells in atherosclerotic plaques and in lymphomas, and improved the survival of transplanted pancreatic islets."These inflammatory monocytes are involved in almost every major disease," Nahrendorf explains. "Anti-inflammatory drugs currently on the market hit every inflammatory cell in the body, which can produce unwanted side effects. This new siRNA treatment doesn't affect inflammatory cells that don't rely on the CCR2 receptor. That makes a big difference."

BEIJING, Jan. 26 (Xinhua) -- China will firmly stand together with African countries while unswervingly pushing forward Sino-African strategic partnership, no matter how the international environment changes, said Chinese Vice Foreign Minister Zhai Jun Thursday.Zhai made the remarks in a signed article on top Chinese political advisor Jia Qinglin's upcoming visit to Africa.Africa still faced enormous challenges against the backdrop of simmering global finance crisis, and turbulence encountered by several countries in western Asia and northern Africa, which dealt a blow to Africa's peace, stability and development, Zhai said, adding that some outside forces' intervention into Africa's internal affairs impeded the integration process among African countries.Within this context, there is stronger demand of African countries for stability, development, solidarity and independence, he said.The international community should pay more attention to Africa's voice and problems, respect its opinions, accommodate its concerns, protect peace, stability and development in Africa, and support Africa's independent settlement of issues in its own region, Zhai said.He said Jia's visit, first foreign trip paid by Chinese leaders in the Chinese Lunar New Year, will be of great significance in deepening Sino-African ties and cementing the solidarity and cooperation among developing countries, Zhai said.Jia will declare China's determination on developing Sino-African ties during the trip, he said.Enhancing solidarity and cooperation with Africa constitutes an important part of China's diplomacy, and will be the long-term strategic choice firmly pursued by China, Zhai said.